Evidence for antinociceptive activity of botulinum toxin type A in pain management

Headache

Volumn 43, Issue SUPPL. 1, 2003, Pages 9-15

  Aoki, K Roger ^a  

^a ALLERGAN INC   (United States)

Author keywords

Antinociceptive; Botulinum; Mechanism; Pain

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; GLUTAMIC ACID; PROTEIN FOS; SUBSTANCE P;

ANTINOCICEPTION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HEADACHE; HUMAN; IMMEDIATE EARLY GENE; MIGRAINE; MUSCLE SPASM; MUSCLE SPINDLE; MYOFASCIAL PAIN; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; NONHUMAN; ONCOGENE C FOS; PAIN; PRIORITY JOURNAL; SENSITIZATION; SIGNAL TRANSDUCTION; TOXIN ANALYSIS;

EID: 0042232400     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.43.7s.3.x     Document Type: Conference Paper

References (18)

1. Smith CP, Somogyi GT, Chancellor MB. Botulinum toxin: poisoning the spastic bladder and urethra. Rev Urol. 2002;4:61-68.
2. Gill DM. Bacterial Toxins: A Fable of Lethal Amounts. Microbiological Reviews. 1982;46:86-94.
3. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001;2:1649-1654.
4. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-S168.
5. Aoki KR. Basic aspects of botulinum toxin: physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol. 2002;30:107-116.
6. Cui M, Aoki KR. Botulinum toxin type A (BONT/A) reduces inflammatory pain in the rat formalin model [abstract]. Cephalalgia. 2000;20:414.
7. Cui M, Li S, You S, Khanijou S, Aoki KR. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing [abstract]. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl 2):R17.
8. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(suppl 1):3-10.
9. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(suppl 5):21-29.
10. Rosales RL, Arimura K, Ikenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve. 1996;19:488-496.
11. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400-404.
12. Ishikawa, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106-109.
13. Deleu D, Hanssens Y, Worthing EA. Symptomatic and prophylactic treatment of migraine: a critical reappraisal. Clin Neuropharmacol. 1998;21:267-279.
14. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245-258.
15. Hoffman GE, Lyo D. Anatomical markers of activity in neuroendocrine systems: are we all 'fos-ed out'? J Neuroendocrinol. 2002;14:259-268.
16. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
17. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15(suppl 3):28-35.
18. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil B, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.